Skip to main content
New GLP-1 protocol guide just published Read →

Semax Inhibits Enkephalin-Degrading Enzymes in the Rat Brain

Kost NV, Sokolov OY, Gabaeva MV, et al.

Peptides/2001/Animal mechanistic study

Background

Semax’s nootropic and neuroprotective effects had been attributed primarily to its interactions with the melanocortin/ACTH receptor system. However, its broader pharmacological profile — including anxiolytic, analgesic, and mood-stabilizing properties not typical of ACTH(4-10) analogs — suggested additional mechanisms.

Kost and colleagues investigated whether Semax could modulate the endogenous opioid system by inhibiting peptidases that degrade enkephalins (endogenous opioid pentapeptides). Enkephalins regulate pain perception, stress responses, mood, and reward — making enkephalin-degrading enzyme inhibition a mechanistically important additional target.

Key Findings

Enzyme Inhibition:

  • Semax (50 µg/kg intranasal) significantly inhibited dipeptidyl peptidase IV (DPP-IV) activity in hippocampus (−34%, p < 0.01) and striatum (−28%, p < 0.05) at 1h post-administration
  • Neutral endopeptidase (NEP/neprilysin) activity also reduced in hippocampus (−22%)
  • Both enzymes are primary degraders of Met-enkephalin and Leu-enkephalin

Functional Consequence:

  • Ex vivo enkephalin stability was significantly prolonged in brain homogenates from Semax-treated animals
  • In vivo analgesia (hot plate test): Semax prolonged nociceptive latency by 38% — an effect blocked by naloxone (opioid antagonist), confirming opioid mechanism contribution

Regional Distribution:

  • DPP-IV inhibition most pronounced in limbic regions (hippocampus, amygdala) — consistent with anxiolytic and mood effects
  • Striatal effects may contribute to Semax’s motor coordination and stress coping actions

Mechanistic Significance

MechanismSemax ActionFunctional Effect
Melanocortin receptor agonismACTH(4-10) mimicryCognitive enhancement, attention
DPP-IV/NEP inhibitionEnkephalin preservationAnxiolysis, analgesia, mood
BDNF upregulationNeurotrophin inductionNeuroplasticity, neuroprotection
Monoamine modulationDopamine/serotonin effectsMotivation, concentration

The discovery that Semax works through both melanocortin receptors AND enkephalin system modulation explains its unusually broad nootropic and anxiolytic profile compared to pure ACTH analogs.

Clinical Significance

  1. Stress and pain comorbidity: The enkephalin-sparing mechanism addresses both anxiety and pain — relevant for patients with comorbid stress-related and pain disorders
  2. Non-opioid opioid augmentation: Unlike direct opioids, increasing endogenous enkephalin availability through enzyme inhibition is thought to have lower addiction potential due to receptor compartmentalization
  3. Mechanistic basis for anxiolysis: The limbic DPP-IV inhibition explains Semax’s anxiolytic effects seen clinically, providing a target separate from its ACTH-related cognitive actions

Limitations

  • Animal study — enkephalin system pharmacology differs between rodents and humans
  • In vitro enzyme activity measurements do not confirm equivalent in vivo CNS enzyme inhibition at clinically used doses
  • Long-term DPP-IV inhibition and its metabolic consequences (DPP-IV also degrades GLP-1) were not assessed
  • No direct measurement of brain enkephalin levels in vivo confirming the enzyme inhibition translates to functionally elevated enkephalin concentrations

Compounds Studied

Semax

Related Conditions

Cognitive HealthNeuroprotection

Related Studies

2016 EL2
Semax, an Analog of ACTH(4-10) with Long-Lasting Anxiolytic and Nootropic Activity, Stimulates BDNF and TrkB Production in Rat Hippocampus

Semax nasal spray significantly improved neurological function scores (NIHSS) and reduced early neurological deficit in ischemic stroke patients compared to standard therapy alone, with concurrent BDNF upregulation in animal models.
2008 EL2
Effects of Semax on EEG Coherence in Patients with Cerebrovascular Disease

Semax (400–600 µg/day intranasal) over 10 days significantly increased EEG coherence in alpha and theta bands between frontal and posterior brain regions in cerebrovascular disease patients, correlating with improvements in attention and short-term memory performance.
2006 EL3
Semax Stimulates BDNF and TrkB Expression in the Rat Hippocampus

Semax (50 µg/kg intranasal) rapidly and significantly increased BDNF mRNA and protein levels in rat hippocampus within 1–24 hours, with concomitant upregulation of the TrkB receptor — providing a mechanistic basis for Semax's reported cognitive and neuroprotective effects.
<- Research Database